RNA-targeted medicines developer building out its own commercial launch engine
Ionis develops RNA-targeted therapeutics and is now staffing up to commercialize its first wholly owned product, with hiring led by sales and skewed heavily toward director-level roles. The stack pairs Veeva and Salesforce Marketing and Data Cloud for field engagement with an SAP S/4HANA ERP rollout and 3PL connectivity work, which points to an R&D shop building full commercial and supply-chain infrastructure.
Notable leadership hires: Director
Ionis Pharmaceuticals is a public biotechnology company founded in 1989 and headquartered in Carlsbad, California, with 501–1,000 employees. It develops RNA-targeted medicines, with a pipeline spanning neurology, cardiology and other areas of high unmet need, and is also advancing gene editing approaches. Its research work relies on methods such as RNA-seq, ChIP-seq, qPCR and LC-MS. Current hiring spans sales, research, healthcare, manufacturing, operations and legal functions in the United States and Ireland.
Ionis uses Veeva, Salesforce (including Marketing Cloud and Data Cloud), SAP S/4HANA, Coupa, UKG, Databricks, Python, Azure, AWS with AWS CDK, Okta, Smartsheet and Microsoft Power Platform.
Yes. Sales is the largest hiring area, and hiring is accelerating, with a director-heavy mix tied to the launch of its first wholly owned commercial product. Roles are in the United States and Ireland.
Ionis is launching its first wholly owned commercial product and expanding an indication from FCS to sHTG. It is also rolling out an ERP system, integrating with a 3PL and preparing global value dossiers and JCA submissions.
Other companies in the same industry, closest in size
Ionis Pharmaceuticals, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.